Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $11.0 million.

  • Gain Therapeutics' Liabilities and Shareholders Equity fell 2362.57% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.6 million, marking a year-over-year decrease of 3325.14%. This contributed to the annual value of $12.1 million for FY2024, which is 3485.05% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Liabilities and Shareholders Equity is $11.0 million, which was down 2362.57% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Liabilities and Shareholders Equity registered a high of $48.0 million during Q1 2021, and its lowest value of $9.8 million during Q2 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $19.2 million (2024), whereas its average is $24.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 30591.02% in 2021, then plummeted by 5023.08% in 2023.
  • Quarter analysis of 5 years shows Gain Therapeutics' Liabilities and Shareholders Equity stood at $39.0 million in 2021, then tumbled by 38.18% to $24.1 million in 2022, then fell by 22.78% to $18.6 million in 2023, then plummeted by 34.85% to $12.1 million in 2024, then dropped by 9.5% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $9.8 million for Q2 2025, and $11.6 million during Q1 2025.